Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma (PHOX)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological, Drug, Other, Procedure, Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This phase II trial tests how well preoperative (prior to surgery) radiation therapy with fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) works for the treatment of stage I-III esophageal or gastroesophageal junction adenocarcinoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Fluorouracil stops cells from making deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is not a chemotherapy medication but is given in conjunction with chemotherapy. Leucovorin is used with the chemotherapy medication fluorouracil to enhance the effects of the fluorouracil, in other words, to make the drug work better. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Giving preoperative hypofractionated radiation with fluorouracil and oxaliplatin may kill more tumor cells in patients with stage I-III esophageal or gastroesophageal junction adenocarcinoma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Histological confirmation of esophageal or gastroesophageal junction adenocarcinoma, American Joint Committee on Cancer (AJCC) 8th edition stage T1-4N0-3M0

• Candidate for trimodality therapy: neoadjuvant chemo (immuno) therapy, chemoradiation, and esophagectomy

• Surgical consultation has confirmed that patient is an appropriate candidate for esophagectomy

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

• Negative pregnancy test done ≤ 7 days prior to chemotherapy, for women of childbearing potential only

• Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance

• Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)

• Willing to provide blood and tissue samples for correlative research purposes

Locations
United States
Arizona
Mayo Clinic in Arizona
NOT_YET_RECRUITING
Scottsdale
Florida
Mayo Clinic in Florida
ACTIVE_NOT_RECRUITING
Jacksonville
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Clinical Trials Referral Office
mayocliniccancerstudies@mayo.edu
855-776-0015
Time Frame
Start Date: 2023-11-20
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 99
Treatments
Experimental: Treatment (FLOT and Radiation and FOLFOX)
Patients received Induction Chemotherapy \[FLOT (5-FU/leucovorin/oxaliplatin/docetaxel)\] following by radiation therapy daily for 3 weeks with 2 concurrent cycles of FOLFOX per protocol. See detailed description for more information.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov

Similar Clinical Trials